KLP Kapitalforvaltning AS Purchases Shares of 5,400 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

KLP Kapitalforvaltning AS bought a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,400 shares of the company's stock, valued at approximately $299,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its stake in shares of Tarsus Pharmaceuticals by 10.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 290,009 shares of the company's stock worth $9,538,000 after acquiring an additional 28,130 shares in the last quarter. FMR LLC boosted its position in Tarsus Pharmaceuticals by 236.6% during the third quarter. FMR LLC now owns 5,032 shares of the company's stock worth $166,000 after purchasing an additional 3,537 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Tarsus Pharmaceuticals by 10.7% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,835 shares of the company's stock worth $1,935,000 after purchasing an additional 5,709 shares in the last quarter. Verition Fund Management LLC acquired a new stake in Tarsus Pharmaceuticals in the third quarter valued at $763,000. Finally, Wellington Management Group LLP increased its position in shares of Tarsus Pharmaceuticals by 14.2% in the third quarter. Wellington Management Group LLP now owns 145,347 shares of the company's stock valued at $4,780,000 after buying an additional 18,019 shares in the last quarter. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

Several research firms recently commented on TARS. Guggenheim reiterated a "buy" rating and issued a $78.00 price objective (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Jefferies Financial Group upped their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Oppenheimer increased their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. HC Wainwright restated a "buy" rating and set a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Finally, Barclays lowered their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $63.67.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, General Counsel Bryan Wahl sold 3,341 shares of the company's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $154,654.89. Following the completion of the sale, the general counsel now directly owns 58,057 shares in the company, valued at $2,687,458.53. This represents a 5.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Dianne C. Whitfield sold 2,315 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $107,161.35. Following the completion of the transaction, the insider now directly owns 50,751 shares in the company, valued at $2,349,263.79. This trade represents a 4.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 32,542 shares of company stock worth $1,581,173 in the last 90 days. 8.25% of the stock is owned by company insiders.

Tarsus Pharmaceuticals Trading Up 5.2 %

NASDAQ TARS traded up $2.31 during mid-day trading on Friday, reaching $46.43. 781,138 shares of the stock were exchanged, compared to its average volume of 681,505. The stock has a market capitalization of $1.78 billion, a PE ratio of -12.19 and a beta of 0.94. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals, Inc. has a 1-year low of $20.08 and a 1-year high of $57.28. The business's fifty day simple moving average is $48.17 and its 200 day simple moving average is $47.22.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.08. The company had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. On average, research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.